Bio Essence Corp (BIOE): Operating Cash Flow
$1.57M
Year ended 2025-12-31
$1.08M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.57M | +151.6% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $623.9K | n/m | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | -$1.03M | n/m | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | -$703.2K | n/m | 2024-04-15, From 2022-01-01 |
| 2021-12-31 | -$1.29M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$732.7K | n/a | 2022-03-31, From 2020-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Bio Essence Corp (BIOE) | 2025-12-31 | $1.57M | +151.6% |
| Lipocine Inc. (LPCN) | 2025-12-31 | -$9.76M | n/m |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | -$129.06M | n/m |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | -$3.31M | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$18.71M | n/m |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | -$21.47M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$14.11M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | -$1.83M | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$44.76M | n/m |
Compare BIOE, LPCN, DNTH, KRSA side by side · Screen every company in Pharmaceutical Preparations ↗